Special Issue "Probiotics and Prebiotics"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 March 2012)

Special Issue Editor

Guest Editor
Prof. Dr. Yasuhiro Koga
Laboratory for Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan
E-Mail: yasuhiro@is.icc.u-tokai.ac.jp
Interests: probiotics; prebiotics; bifidobacteria; gnotobiology; helicobacter pylori; stomach; atopic dermatitis; gut-brain axis

Special Issue Information

Dear Colleagues,

Probiotics are defined as live non-pathogenic bacteria that beneficially affect the host by influencing the microbiota of the digestive tract. Prebiotics, that are usually saccharides and fiber, represent a source of energy being metabolized by the intestinal and probiotic microbiota. In the last several decades, a rapid enlargement in the use of probiotics/prebiotics occurred for prevention and treatment of diseases in medicine, such as diarrhea caused by certain pathogenic bacteria and viruses, Helicobacter pylori infection, and allergy etc. Rigid evidence supporting the efficacy of probiotics/prebiotics in such clinical uses and mechanical studies are now needed in order to firmly establish them in the modern medicine.

Prof. Dr. Yasuhiro Koga
Guest Editor

Keywords

  • probiotics
  • prebiotics
  • prevention of diarrhea caused by pathogenic bacteria and viruses
  • Helicobacter pylori infection and complications
  • inflammatory bowel diseases
  • irritable bowel syndrome
  • mucosal immunity
  • allergy
  • hyperlipidemia
  • gut-brain axis

Published Papers (6 papers)

Pharmaceuticals 2012, 5(7), 727-744; doi:10.3390/ph5070727
Received: 12 April 2012; in revised form: 26 June 2012 / Accepted: 29 June 2012 / Published: 6 July 2012
Show/Hide Abstract | Download PDF Full-text (181 KB) | Download XML Full-text

Pharmaceuticals 2012, 5(6), 665-673; doi:10.3390/ph5060665
Received: 7 May 2012; in revised form: 13 June 2012 / Accepted: 15 June 2012 / Published: 19 June 2012
Show/Hide Abstract | Download PDF Full-text (205 KB) | Download XML Full-text
abstract graphic

Pharmaceuticals 2012, 5(6), 655-664; doi:10.3390/ph5060655
Received: 16 May 2012; in revised form: 4 June 2012 / Accepted: 6 June 2012 / Published: 19 June 2012
Show/Hide Abstract | Download PDF Full-text (570 KB) | Download XML Full-text

Pharmaceuticals 2012, 5(6), 629-642; doi:10.3390/ph5060629
Received: 1 April 2012; in revised form: 29 May 2012 / Accepted: 5 June 2012 / Published: 18 June 2012
Show/Hide Abstract | Download PDF Full-text (73 KB) | Download XML Full-text

Pharmaceuticals 2012, 5(5), 481-492; doi:10.3390/ph5050481
Received: 11 April 2012; in revised form: 9 May 2012 / Accepted: 11 May 2012 / Published: 15 May 2012
Show/Hide Abstract | Download PDF Full-text (228 KB) | Download XML Full-text

Pharmaceuticals 2012, 5(2), 236-248; doi:10.3390/ph5020236
Received: 23 December 2011; in revised form: 3 February 2012 / Accepted: 10 February 2012 / Published: 16 February 2012
Show/Hide Abstract | Download PDF Full-text (726 KB) | Download XML Full-text

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert